首页> 外文期刊>Peritoneal dialysis international: Journal of the International Society for Peritoneal Dialysis >Identification of hepatitis C virus RNA in peritoneal dialysis fluid of patients with viremia.
【24h】

Identification of hepatitis C virus RNA in peritoneal dialysis fluid of patients with viremia.

机译:病毒血症患者腹膜透析液中丙型肝炎病毒RNA的鉴定。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: The potential risk for transmission of hepatitis C virus (HCV) by peritoneal dialysis (PD) has been studied previously, with conflicting results. METHODS: To assess whether HCV crosses the peritoneal membrane, the following determinations were performed in 16 patients (7 males, 9 females; mean age 41.8 years; mean time on PD 14 +/- 15 months) undergoing PD: serum anti-HCV using second-generation enzyme-linked immunosorbent assay (ELISA), serum and PD fluid HCV RNA by nested polymerase chain reaction, HCV genotyping by restriction fragment length polymorphism, and serum HCV load by branched DNA assay. RESULTS: Anti-HCV was positive in 10 patients. Serum HCV RNA was positive in 7 anti-HCV-positive patients and negative in all anti-HCV-negative patients. Fluid HCV RNA was detected in 5 (71.4%) patients testing positive for serum HCV RNA and in none testing negative for serum HCV RNA. Serum HCV genotype was 1a in 3 patients and 1b in 4; PD fluid HCV genotype was 1a in 1 patient and 1b in 4. Genotypes in serum and fluid were concordant when both were positive. Serum viral load ranged from nondetectable by the quantitative method to 5.1 MEq genome/mL in patients with fluid infection, and 1.05 MEq and 29 MEq genome/mL in the remaining 2 patients without detectable HCV in PD fLuid. CONCLUSIONS: HCV crosses the peritoneal membrane and may be detected in the dialysate of PD patients with proven viremia. Although our study population was small for firm conclusions to be drawn, this passage does not seem to depend upon the serum viral load. Our data support the notion that PD fluid needs careful handling and local disinfection to prevent possible spreading of viruses, in the institutional and the domestic environments.
机译:背景:先前已经研究了通过腹膜透析(PD)传播丙型肝炎病毒(HCV)的潜在风险,但结果相互矛盾。方法:为评估HCV是否穿过腹膜,在接受PD治疗的16例患者中进行了以下测定(男7例,女9例;平均年龄41.8岁;平均PD时间14 +/- 15个月):第二代酶联免疫吸附试验(ELISA),巢式聚合酶链反应检测血清和PD液HCV RNA,限制性酶切片段长度多态性检测HCV基因型和分支DNA检测血清HCV载量。结果:10例患者的抗-HCV阳性。 7例抗HCV阳性患者的血清HCV RNA阳性,而所有抗HCV阴性患者的血清HCV RNA阴性。在5例(71.4%)血清HCV RNA呈阳性,血清HCV RNA呈阴性的患者中检测到了HCV RNA。 3例患者的血清HCV基因型为1a,4例为1b。 1名患者的PD液HCV基因型为1a,4例为1b。当两者均为阳性时,血清和体液的基因型一致。在液体感染患者中,血清病毒载量范围从无法通过定量方法检测到5.1 MEq基因组/ mL,在其余2例在PD流体中未检测到HCV的患者中,分别为1.05 MEq和29 MEq基因组/ mL。结论:HCV穿过腹膜,可能在证实病毒血症的PD患者的透析液中检测到。尽管我们的研究人群很小,无法得出肯定的结论,但这一传言似乎并不取决于血清病毒载量。我们的数据支持以下观点:PD液体需要在机构和家庭环境中进行仔细处理和局部消毒,以防止可能的病毒传播。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号